摘要
脓毒症是感染引起宿主免疫应答失调导致危及生命的器官功能障碍,致死率高,缺乏有效治疗药物。脓毒症发病机制复杂,涉及感染病原微生物及其毒素对宿主机体引起的全身炎症网络效应、免疫抑制与凝血功能障碍、内皮屏障损伤等多个方面,与机体多系统失常、多器官功能障碍、多脏器衰竭的病理生理改变密切相关。近年来全球范围内脓毒症发病率不断上升,每年增幅9%。脓毒症疾病的发展并不依赖所感染的病原微生物,后期炎症风暴导致严重的病情,使得脓毒症临床治疗十分棘手。而目前单纯应用抗生素治疗脓毒症效果并不理想,大多数临床治疗手段治标不治本,所以根据脓毒症患者病理生理过程探寻分子机制并据此设计的药物受到越来越多研究学者关注。本文主要综述根据其病理生理过程设计的靶点药物。
Sepsis is a refractory disease with high mortality in which the host’s immune response to the infection is dysfunctional,resulting in life-threatening organ function damage.The pathogenesis of sepsis is complex,involving systemic inflammation,immunosuppressive and coagulation abnormalities,and endothelial barrier damage caused by the infecting pathogenic microorganisms and their toxins.The pathogenesis of sepsis is closely related to multiple systems disorder and multiple organ dysfunction and failure.In recent years,the incidence of sepsis has been increasing globally,with an annual increase of 9%.Since the development of sepsis does not depend on the infecting pathogenic microorganisms and the late inflammatory reaction can be life-threatening,clinical treatment of sepsis can be very difficult.However,the current antibiotic treatments for sepsis are not ideal.Most clinical treatments are not curative,so researchers seek new drug designs based on exploring molecular mechanisms of the pathophysiological process in sepsis patients.This paper reviews the recent development of drugs designed according to the sepsis pathophysiological process.
作者
谢春阳
王秀坤
游雪甫
XIE Chun-yang;WANG Xiu-kun;YOU Xue-fu(Beijing Key Laboratory of Antimicrobial Agents,Institute of Medicinal Biotechnology,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China)
出处
《药学学报》
CAS
CSCD
北大核心
2020年第3期413-420,共8页
Acta Pharmaceutica Sinica
基金
中国医学科学院医学与健康科技创新工程(2016-12M-3-014)
“十三五”国家科技重大专项(2019ZX09721001)
国家自然科学基金资助项目(81621064).
作者简介
通讯作者:游雪甫,Tel:13311123098,Fax:86-10-67010489,E-mail:xuefuyou@imb.pumc.edu.cn
